A technique can consistently achieve thicknesses of ≤ 50 .Math.m for corneal tissue for for Descemet stripping automated endothelial keratoplasty (DSAEK). Grafts with thicknesses of ≤ 50 .Math.m are also known as nanothin DSAEK (NT-DSAEK) grafts. Evidence shows that using thinner DSAEK grafts, particularly NT-DSAEK grafts, can significantly improve visual outcomes. According to an example embodiment, a method for producing a corneal graft includes drying a donor cornea to cause a pre-cut thickness of the donor cornea to decrease. The method includes, concurrently with drying the donor cornea, determining pre-cut thickness measurements for the donor cornea. The method includes, in response to the precut thickness measurements indicating the pre-cut thickness of the donor cornea has decreased to a predetermined value, cutting the donor cornea to a post-cut thickness of ≤ 100 .Math.m, or more particularly ≤ 50 .Math.m, to produce a corneal graft.

Disclosed is a biocomposite product with high microbial activity obtained by using bee bread, the method of obtaining this product and using of this biocomposite material for the coating of products like artificial materials, packaging, etc. to be used in areas requiring hygiene or their use as an intermediate raw material.

Grafts modified with one or more bioactive substances are provided, as well as methods to make and use them. More particularly, the present invention relates to modified grafts having characteristics which facilitate tissue generation, repair, and reconstruction, and which are modified with bioactive substances, such as one or more proteins and minerals, whose bioactivity further facilitates tissue generation, repair, and reconstruction. Methods for producing the modified grafts include depositing the one or more bioactive substances onto, into, or both, a substrate material. In certain exemplary embodiments, the substrate material comprises a tissue derived matrix produced by processing one or more tissue samples, and the bioactive materials are precipitated from a solution produced during that processing, such as during demineralization of bone tissue samples or delipidation of adipose tissue samples, wherein the one or more bioactive substances comprise proteins and minerals endogenous to bone or adipose tissue, respectively.

Disclosed is a method of producing reconstructed human skin including forming a three-dimensional hydrogel scaffold matrix by gelling a matrix solution including a type I collagen solution, forming a coating layer by coating the three-dimensional hydrogel scaffold matrix with type IV collagen, and forming an epidermis by seeding epidermal keratinocytes onto the three-dimensional hydrogel scaffold matrix having the coating layer formed thereon and performing culture.

Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.

Methods for making surgical implants (or grafts) for the repair of bone defects, and more particularly, surgical implants that include demineralized bone fibers, are disclosed. Also disclosed are methods for increasing the wettability and ensuring uniform density of such implants. The surgical implants have a wettability time of less than 5 minutes and a residual moisture content of less than 6% by weight, and they remain cohesive and retain their shape upon complete rehydration.

A bone grinder is provided herein. The bone grinder may have a grinding chamber, an intermediate zone, and a primary cutting element and a secondary cutting element. The intermediate zone may have a first wall and a second wall within the grinding chamber, and the intermediate zone may separate the primary cutting element from the secondary cutting element. The first wall and the second wall may slope inward such that a distance between the first wall and the second wall generally decreases from the primary cutting element to the secondary cutting element. The primary cutting element and the secondary cutting element may be positioned within the grinding chamber to sequentially perform primary cutting operations and secondary cutting operations on a bone. A drive mechanism may operatively engage the primary cutting element and the secondary cutting element.

The present invention relates to a tissue adhesion agent having improved bio-tissue adhesiveness and bonding force by utilizing an adhesion-related gene. More specifically, a cartilage tissue adhesion composition prepared from fetal cartilage tissue-derived stem cells in which VCAN, CTGF, or EXT1 is inserted and expressed in an upregulated manner was found to show a remarkably superb adhesive force, compared to that prepared from fetal cartilage tissue-derived stem cells in which none of the genes are inserted. Accordingly, the cell composition in which the expression of VCAN, CTGF, or EXT1 is upregulated can be prepared into a tissue adhesion composition having improved bio-tissue adhesiveness and bonding force and VCAN, CTGF, or EXT1 can be provided as an additive composition for a tissue adhesion agent.

The present invention relates to a tissue adhesion agent having improved bio-tissue adhesiveness and bonding force by utilizing an adhesion-related gene. More specifically, a cartilage tissue adhesion composition prepared from fetal cartilage tissue-derived stem cells in which VCAN, CTGF, or EXT1 is inserted and expressed in an upregulated manner was found to show a remarkably superb adhesive force, compared to that prepared from fetal cartilage tissue-derived stem cells in which none of the genes are inserted. Accordingly, the cell composition in which the expression of VCAN, CTGF, or EXT1 is upregulated can be prepared into a tissue adhesion composition having improved bio-tissue adhesiveness and bonding force and VCAN, CTGF, or EXT1 can be provided as an additive composition for a tissue adhesion agent.

Systems, devices, and methods for treating a nerve injury in a patient are provided. The system includes an extracellular matrix, a neutralizing element, and a reconstituting element. The extracellular matrix is configured to promote and/or sustain the growth of tissue and/or associated tissue properties proximate the nerve injury.